Latest Conference Articles

January 25th 2017, 1:47am

Gastrointestinal Cancers Symposium (ASCO GI)

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the recent surgical advancements in pancreatic cancer.

January 25th 2017, 1:34am

Gastrointestinal Cancers Symposium (ASCO GI)

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

January 22nd 2017, 3:24am

Gastrointestinal Cancers Symposium (ASCO GI)

Arturo Loaiza-Bonilla, MD, medical oncologist, the University of Pennsylvania, discusses a study investigating differences in mutation rates between right- and left-sided colorectal cancer.

January 22nd 2017, 12:04am

Gastrointestinal Cancers Symposium (ASCO GI)

In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.

January 22nd 2017, 12:00am

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

January 21st 2017, 8:46pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.

January 21st 2017, 8:05pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.

January 21st 2017, 7:48am

Gastrointestinal Cancers Symposium (ASCO GI)

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

January 21st 2017, 6:51am

Gastrointestinal Cancers Symposium (ASCO GI)

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.

January 21st 2017, 2:10am

Gastrointestinal Cancers Symposium (ASCO GI)

Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

January 21st 2017, 12:11am

Gastrointestinal Cancers Symposium (ASCO GI)

Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.

January 20th 2017, 10:45pm

Gastrointestinal Cancers Symposium (ASCO GI)

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

January 20th 2017, 5:52am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

January 20th 2017, 4:19am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

January 20th 2017, 1:18am

Gastrointestinal Cancers Symposium (ASCO GI)

​Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

January 18th 2017, 3:05am

Gastrointestinal Cancers Symposium (ASCO GI)

Switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy improved pathologic complete response rates in patients with esophageal and gastroesophageal junction cancers.

January 18th 2017, 2:37am

Gastrointestinal Cancers Symposium (ASCO GI)

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.

January 18th 2017, 2:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

December 10th 2016, 5:28am

San Antonio Breast Cancer Symposium

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

December 10th 2016, 5:15am

San Antonio Breast Cancer Symposium

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).